Cell Therapy Market Size, Share, & Trends Report

Cell Therapy Market Size, Share, & Trends Analysis Report By Use (Clinical, Research), By Type (Stem & Non-stem Cells) By Therapy Type (Autologous, Allogenic), By Region, And Segment Forecasts, 2018 - 2025

  • Published Date: Nov, 2018
  • Base Year for Estimate: 2017
  • Report ID: GVR-2-68038-701-8
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2017
  • Number of Pages: 120

Industry Insights

The global cell therapy market size was valued at USD 5.22 billion in 2017. It is likely to expand at a CAGR of 5.34% during the forecast period. The market is poised to benefit from the inclusion of new cell types, which in turn, provide substantial opportunities to companies to reinforce their market position. As a result, the number of companies involved in cell therapy development has increased tremendously over the past years.

Rising funding from government as well as private organizations to support cell therapy clinical trials, introduction of effective guidelines for cell therapy manufacturing, and proven effectiveness of products are some of the primary growth stimulants for the market. In addition, declining prices of stem cell therapies are leading to increased inclination of buyers towards cell therapy.

Japan cell therapy market

Development of cell banking facilities and resultant expansion of production, storage, and characterization of cells are enhancing volumetric capabilities of the cytotherapy market at a global level. This, in turn, has directly translated into increase in revenue generation for the stem cells and non-stem cells therapy market in the past years.

Furthermore, regulatory bodies are engaged in providing support to innovators for introduction of novel and effective solutions for patients as quickly as possible. Moreover, existing companies are working in collaboration with regulatory agencies in order to best fit into regulatory model for cell therapies.

Despite being slightly ethically as well as legally controversial, the market is gaining significant attention from entities involved in various aspects of disease management. Healthcare practitioners are making significant use of stem cells derived from bone marrow or blood in transplant procedures for treatment of patients with cancer, blood disorders, and immune-related disorders.

Furthermore, the market is largely influenced by commercialization of unauthorized stem cell treatments. As of June 2016, there were around 351 companies across the U.S. that were engaged in advertising unauthorized stem cell treatments at their clinics. Such clinics boosted the revenue in this market.

However, in August 2017, the U.S. FDA announced increased enforcement of regulations and oversight of clinics involved in practicing unapproved stem cell therapies. This might hamper the revenue generation during the forecast period; nevertheless, it will allow safe and effective use of stem cell therapies.

Use & Type Insights

There are a limited number of FDA approved stem and non-stem cell therapies in the market for commercial usage. Thus, the stem cells and non-stem cells market for clinical-use accounted for a lesser share in 2017, compared to the research-use segment. Furthermore, wind down of LAVIV (Azficel-T) in 2017, manufactured and offered by Fibrocell Technologies, has reduced the revenue growth to a certain extent in 2017.

Some examples of approved cell therapies for clinical applications are MACI, Epicel, Cellgram-AMI, Cupistem, Cellistem IC CARTISTEM, Invossa, Prochymal, Imlygic, and GINTUIT. The market for clinical-use is further bifurcated into stem cell-based and non-stem cell-based therapies. Non-stem cell therapies comprising therapies developed from collagen-producing fibroblast cells, immune cells, cartilage cells, keratinocytes, and others are poised to witness noteworthy growth during the forecast period.

On the flip side, stem cell therapies derived from blood cells, adipose tissues, and others are projected to witness a decline in their revenue growth. This decline can be attributed to tedious and elaborated process of cell production.

Therapy Type Insights

Across the globe, development and sales of allogeneic stem cell therapies has been greater than autologous therapies. The high cost associated with the former coupled with presence of a relatively large number of market entities involved in this therapy development has led to a larger share of the segment in the global cell therapy market (stem cells & non-stem cells).

Kolon TissueGene, Inc.; JCR Pharmaceuticals Co., Ltd.; and MEDIPOST are some of the companies that are engaged in catering products in this segment. However, the market exhibits growth potential for both allogeneic and autologous therapies.

Global stem cells & non-stem cells market

Autologous therapies are anticipated to register a significant rate during the forecast period owing to several advantages offered by them such as availability, lower risk of life-threatening complications, low rate of graft failure, low mortality rate, higher affordability, and high survival rate of patients. Some companies that are involved in delivering autologous therapies are Fibrocell Technologies, Vericel Corporation, and Dendreon.

Regional Insights

North America is projected to hold the largest share in the global market throughout the forecast horizon. Strong regulatory framework for promoting cellular therapy development, high cost of therapies in the U.S., and presence of a raft of companies are promoting the growth of the regional market. The U.S. is estimated to be the leading revenue contributor in the region. However, as compared to current U.S. market, Canadian market accounted for a lesser share in the North America cellular therapy market.

The Asia Pacific market is anticipated to experience the highest growth during the same period. Rising investments by developers and consumers in educating themselves for advanced medicinal therapies are expected to stimulate the growth of the market in emerging economies of this region.

Pricing of stem cell transplant varies from region to region. For instance, cost of transplantation in the U.S. is observed to be costlier than that in Germany or China. Furthermore, revenue for certain products varies in different countries owing to different approval policies. For instance, products such as Invossa, Cupistem, and Cellgram-AMI have received approval from Ministry of Food and Drug Safety for distribution of the product in Korea but is yet to receive marketing authorization in the U.S.

Cell Therapy Market (Stem Cells & Non-Stem Cells) Share Insights

Some of the key companies operating in the market are Kolon TissueGene, Inc.; JCR Pharmaceuticals Co. Ltd.; MEDIPOST; Osiris Therapeutics, Inc.; Stemedica Cell Technologies, Inc.; Cells for Cells; NuVasive, Inc.; Fibrocell Science, Inc.; Vericel Corporation; PHARMICELL Co., Ltd.; ANTEROGEN.CO.,LTD. These companies are collaborating with blood centers and plasma collection centers in order to obtain cells for use in therapeutics development.

Furthermore, companies are undertaking efforts for the expansion of customer base, by promoting it to surgeons for usage in transplantation procedures. For example, in February 2017, Vericel Corporation conducted first implant of MACI in the U.S. for treatment of symptomatic multiple or single full-thickness cartilage defects of the knee. Post this, the company began channelizing its strategies to increase the number of surgeons employing its products in transplantation procedures.

Report Scope

Attribute

Details

Base year for estimation

2017

Actual estimates/Historical data

2014 - 2017

Forecast period

2018 - 2025

Market representation

Revenue in USD Million and CAGR from 2018 to 2025

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Country scope

U.S., Canada, Germany, U.K., China, Japan, Brazil, South Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5-analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization


Segments Covered in the Report

This report forecasts revenue growth at global, regional, & country levels and provides an analysis of industry trends in each of the sub segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global cell therapy market (stem cells & non-stem cells) report on the basis of use-type, therapy-type, and region:

  • Use & Type Outlook (Revenue, USD Million, 2014 - 2025)

    • Clinical-use

      • By Therapeutic Area

        • Malignancies

        • Muscoskeletal Disorders

        • Autoimmune Disorders

        • Dermatology

        • Others

      • By Cell Therapy Type

        • Stem Cell Therapies

          • BM, Blood, & Umbilical Cord-derived Stem Cells

          • Adipose derived cells

          • Others

        • Non-stem Cell Therapies

    • Research-use

  • Therapy Type Outlook (Revenue, USD Million, 2014 - 2025)

    • Allogenic Therapies

    • Autologous Therapies

  • Regional Outlook (Revenue, USD Million, 2014 - 2025)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

    • Asia Pacific

      • China

      • Japan

    • Latin America

      • Brazil

    • Middle East & Africa

      • South Africa

Key questions answered by the report
Request for Customization

Choose License Type

Single User - $5,950
Multi User (2-5) - $7,950
Enterprise Access - $9,950

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

  • Research support

    24/5 Research support

    Get your queries resolved from an industry expert.

  • Custom research service

    Custom research service

    Design an exclusive study to serve your research needs.

  • Quality assurance

    Quality assurance

    A testimonial for service in the form of BBB "A" Accreditation.

  • BBB Rating dandb
  • Information security

    Information security

    Your personal and confidential information is safe and secure.

  • grand view research PCI DSS complaint grand view research paypal verified